Article
Cardiac & Cardiovascular Systems
Dorte Vistisen, Bendix Carstensen, Patorno Elisabetta, Stefanie Lanzinger, Elise Chia-Hui Tan, Daisuke Yabe, Dae Jung Kim, Wayne H. -H. Sheu, Cheli Melzer-Cohen, Reinhard W. Holl, Julio Nunez, Kyoung Hwa Ha, Sigrun Halvorsen, Gisle Langslet, Avraham Karasik, Thomas Nystrom, Leo Niskanen, Sonia Guleria, Riho Klement, Marc Carrasco, Johannes Foersch, Christina Shay, Lisette Koeneman, Fabian Hoti, Soulmaz Fazeli Farsani, Kamlesh Khunti, Francesco Zaccardi, Anuradhaa Subramanian, Krishnarajah Nirantharakumar
Summary: This study compared the risk of cardiovascular events in patients with type 2 diabetes initiating empagliflozin compared to dipeptidyl peptidase-4 inhibitors (DPP-4i) in routine care settings in Europe and Asia. The results showed that regardless of pre-existing cardiovascular disease (CVD) or history of heart failure (HF), the use of empagliflozin resulted in lower risk of cardiovascular events.
CARDIOVASCULAR DIABETOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Yuka Shiheido-Watanabe, Yasuhiro Maejima, Takeshi Kasama, Natsuko Tamura, Shun Nakagama, Yusuke Ito, Kenzo Hirao, Mitsuaki Isobe, Tetsuo Sasano
Summary: The study demonstrated the mechanism of ameliorating experimental autoimmune myocarditis by linagliptin, showing that it reduces Th17 cells infiltration and oxidative stress in EAM hearts. It also found that the interaction between DPP-4 and cathepsin G plays a detrimental role by suppressing SerpinA3N activity.
JACC-BASIC TO TRANSLATIONAL SCIENCE
(2021)
Article
Cardiac & Cardiovascular Systems
Edwin K. Jackson, Zaichuan Mi, Delbert G. Gillespie, Dongmei Cheng, Stevan P. Tofovic
Summary: The long-term use of DPP4 inhibitors in a rat model of spontaneous hypertension, heart failure, diabetes, obesity, and hyperlipidemia resulted in detrimental effects on blood pressure levels, renal function, and cardiac structure, indicating potential harm and the need for further investigation into the mechanisms and prevention of DPP4 inhibitor-induced pathological conditions.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2021)
Article
Medicine, Research & Experimental
Daniel F. Arruda-Junior, Thiago A. Salles, Flavia L. Martins, Ednei L. Antonio, Paulo J. F. Tucci, Luis Henrique W. Gowdak, Caio A. M. Tavares, Adriana C. Girardi
Summary: This study found that there is an interaction between DPP4 and RAS in heart failure rats, and combined inhibition of DPP4 and RAS may not provide additional cardioprotection compared to monotherapy.
Article
Endocrinology & Metabolism
Iskandar Idris, Ruiqi Zhang, Jil Billy Mamza, Mike Ford, Tamsin Morris, Amitava Banerjee, Kamlesh Khunti
Summary: The study found that in patients with type 2 diabetes, sodium-glucose co-transporter-2 inhibitors (SGLT2is) were associated with significantly lower risk of all-cause mortality, cardiovascular death, and hospitalization for heart failure or chronic kidney disease compared to dipeptidyl peptidase-4 inhibitors (DPP4is).
DIABETES OBESITY & METABOLISM
(2021)
Article
Peripheral Vascular Disease
Jessica R. Wilson, Erica M. Garner, Mona Mashayekhi, Scott A. Hubers, Claudia E. Ramirez Bustamante, Scott Jafarian Kerman, Hui Nian, Cyndya A. Shibao, Nancy J. Brown
Summary: DPP4 inhibition may increase catecholamine levels, but does not increase blood pressure. Increased catecholamines during concurrent use of ACE and DPP4 inhibitors may contribute to cardiovascular complications in patients predisposed to heart failure.
Article
Medicine, Research & Experimental
Milene T. Fontes, Daniel F. Arruda-Junior, Danubia Silva dos Santos, Joao Carlos Ribeiro-Silva, Edinei L. Anto, Paulo F. J. Tucci, Luciana V. Rossoni, Adriana C. C. Girardi
Summary: This study tested the effects of DPP4 inhibitor vildagliptin on aortic hyperreactivity in male HF rats. The results showed that DPP4i mitigated the hypercontractility of HF aortas and enhanced NO bioavailability, suggesting a potential protective effect on the arteries.
Article
Endocrinology & Metabolism
Jiaoran Li, Yanping Liu, Panpan Hao
Summary: This study aimed to evaluate the effects of DPP-4i treatment on all-cause mortality and cardiovascular outcomes in patients with heart failure. The results showed that DPP-4i treatment did not reduce the risk of all-cause death, cardiovascular death, or hospitalization for heart failure overall. However, subgroup analyses revealed that DPP-4i significantly reduced all-cause mortality in trials with more than 40% female patients and in trials with more than 20% patients with heart failure with preserved ejection fraction (HFpEF).
DIABETES RESEARCH AND CLINICAL PRACTICE
(2023)
Article
Endocrinology & Metabolism
Da Hea Seo, Kyoung Hwa Ha, So Hun Kim, Dae Jung Kim
Summary: The study showed that among patients with type 2 diabetes mellitus, the use of teneligliptin was not associated with an increased risk of cardiovascular events such as hospitalization for heart failure, but was associated with a lower risk of hypoglycemia compared to sulfonylurea therapy.
ENDOCRINOLOGY AND METABOLISM
(2021)
Article
Endocrinology & Metabolism
Avraham Karasik, Stefanie Lanzinger, Elise Chia -Hui Tan, Daisuke Yabe, Dae Jung Kim, Wayne H. -H Sheu, Cheli Melzer-Cohen, Reinhard W. Holl, Kyoung Hwa Ha, Kamlesh Khunti, Francesco Zaccardi, Anuradhaa Subramanian, Krishnarajah Nirantharakumar, Thomas Nystrom, Leo Niskanen, Majken Linnemann Jensen, Fabian Hoti, Riho Klements, Anouk Deruaz-Luyet, Moe H. Kyaw, Lisette Koeneman, Dorte Vistisen, Bendix Carstensen, Sigrun Halvorsen, Gisle Langslet, Soulmaz Fazeli Farsani, Elisabetta Patorno, Julio Nunez
Summary: This non-interventional cohort study evaluated the cardiovascular and kidney efficacy and safety of empagliflozin in patients with type 2 diabetes compared to dipeptidyl peptidase-4 inhibitors. The results showed that empagliflozin was associated with a lower risk of hospitalization for heart failure, myocardial infarction, stroke, and end-stage renal disease, but a higher risk of diabetic ketoacidosis compared to dipeptidyl peptidase-4 inhibitors. The study provides further evidence of the beneficial cardiorenal effects and overall safety of empagliflozin.
DIABETES & METABOLISM
(2023)
Review
Immunology
Jie Huang, Xinxin Liu, Yingying Wei, Xinlu Li, Shupei Gao, Lingli Dong, Xiaoquan Rao, Jixin Zhong
Summary: DPP4 is a widely expressed protease that alters the bioactivity of its substrates by cleaving off dipeptides from their N-terminus. In addition to its enzymatic functions, DPP4 is involved in various cellular processes and plays a crucial role in immune regulation and autoimmune rheumatic diseases.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Yoshihiro Noguchi, Shunsuke Yoshizawa, Tomoya Tachi, Hitomi Teramachi
Summary: In Japan, DPP-4 inhibitors have a similar risk of cardiovascular events compared to metformin.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Endocrinology & Metabolism
Jui Wang, Hon-Yen Wu, Kuo-Liong Chien
Summary: This study found that DPP4 inhibitors have better cardioprotective effects compared to sulfonylureas in preventing major adverse cardiovascular events. Sitagliptin and vildagliptin showed a significantly lower risk of hospitalization, while saxagliptin showed a borderline significantly higher risk of hospitalization for heart failure.
DIABETES & METABOLISM
(2022)
Review
Medicine, General & Internal
Michael Razavi, Ying-Ying Wei, Xiao-Quan Rao, Ji-Xin Zhong
Summary: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors are commonly used treatments for type 2 diabetes mellitus, but their safety has been questioned.
MILITARY MEDICAL RESEARCH
(2022)
Article
Cardiac & Cardiovascular Systems
Sharen Lee, Jiandong Zhou, Keith Sai Kit Leung, Abraham Ka Chung Wai, Kamalan Jeevaratnam, Emma King, Tong Liu, Wing Tak Wong, Carlin Chang, Ian Chi Kei Wong, Bernard Man Yung Cheung, Gary Tse, Qingpeng Zhang
Summary: Based on real-world data of type 2 diabetic patients in Hong Kong, the use of SGLT2Is was associated with lower risk of incident AF, stroke/transient ischemic attack, and cardiovascular and all-cause mortality outcomes compared to DPP4Is.
CARDIOVASCULAR DRUGS AND THERAPY
(2023)
Article
Immunology
Shu-Chen Kuo, Shu-Man Shih, Tsai-Ling Yang Lauderdale, I-Shou Chang, Yee-Chun Chen, Chao A. Hsiung, Shang-Chwen Chang
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
(2020)
Article
Immunology
Jing-Yi Liu, Tsai-Lien Liao, Wei-Cheng Huang, Yen-Ming Liu, Keh-Ming Wu, Tsai-Ling Lauderdale, Shih-Feng Tsai, Shu-Chen Kuo, Hung-Chih Kuo
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
(2020)
Article
Chemistry, Multidisciplinary
Fang-Hsuean Liao, Te-Haw Wu, Chun-Nien Yao, Shu-Chen Kuo, Chun-Jen Su, U-Ser Jeng, Shu-Yi Lin
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
(2020)
Article
Infectious Diseases
Yi-Tzu Lee, Jun-Ren Sun, Yung-Chih Wang, Chun-Hsiang Chiu, Shu-Chen Kuo, Te-Li Chen, Ya-Sung Yang
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2020)
Article
Microbiology
Ming-Hsien Chiang, Ya-Sung Yang, Jun-Ren Sun, Yung-Chih Wang, Shu-Chen Kuo, Yi-Tzu Lee, Yi-Ping Chuang, Te-Li Chen
FRONTIERS IN MICROBIOLOGY
(2020)
Article
Medicine, Research & Experimental
Hsiao-Hui Tsou, Yu-Chieh Cheng, Hsiang-Yu Yuan, Ya-Ting Hsu, Hsiao-Yu Wu, Fang-Jing Lee, Chao A. Hsiung, Wei J. Chen, Huey-Kang Sytwu, Shiow-Ing Wu, Shu-Man Shih, Tzai-Hung Wen, Shu-Chen Kuo
CONTEMPORARY CLINICAL TRIALS
(2020)
Article
Infectious Diseases
Yung-Chih Wang, Shu-Wei Huang, Ming-Hsien Chiang, I-Ming Lee, Shu-Chen Kuo, Ya-Sung Yang, Chun-Hsiang Chiu, Ying-Shih Su, Te-Li Chen, Fu-Der Wang, Yi-Tzu Lee
Summary: The combination of imipenem and BLI-489 showed synergistic effects against CRAb isolates producing CHDLs, particularly OXA-24, OXA-51, and OXA-58. The results demonstrated significant inhibition and rescue effects on CRAb-infected experimental animals.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2021)
Article
Public, Environmental & Occupational Health
Fang-Yu Kang, Chorng-Kuang How, Yung-Chih Wang, Aristine Cheng, Ya-Sung Yang, Shu-Chen Kuo, Chang-Pan Liu, Yuag-Meng Liu, Te-Li Chen, Yi-Tzu Lee
ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL
(2020)
Article
Infectious Diseases
Shu-Chen Kuo, Mei-Chen Tan, Wei-Cheng Huang, Han-Chieh Wu, Feng-Jui Chen, Yu-Chieh Liao, Hui-Ying Wang, Yih-Ru Shiau, Tsai-Ling Lauderdale
Summary: The study aimed to determine the susceptibilities of Elizabethkingia spp. to various antibiotics, revealing differences in susceptibility among different strains. Discrepancies were observed between the results obtained from traditional methods and an automated system.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2021)
Article
Infectious Diseases
Shu-Chen Kuo, Yung-Chih Wang, Mei-Chen Tan, Wei-Cheng Huang, Yih-Ru Shiau, Hui-Ying Wang, Jui-Fen Lai, I-Wen Huang, Tsai-Ling Lauderdale
Summary: Novel antibiotics zidebactam, avibactam, relebactam, and vaborbactam increased the susceptibility of INS-EC, INS-KP, and INS-PA, while beta-lactam/BLI-BLE combinations were ineffective against INS-AB. INS-EC and INS-KP strains with exclusively bla(KPC-like) genes showed good susceptibility to the mentioned antibiotics.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2021)
Article
Infectious Diseases
Ya-Sung Yang, Tzu-Wen Huang, Ying-Chi Huang, Wei-Cheng Huang, Shu-Yuan Hsu, Han-Chieh Wu, Feng-Jui Chen, Hung-Sheng Shang, Huey-Kang Sytwu, Shu-Chen Kuo
Summary: The study aimed to evaluate the efficacy of minocycline monotherapy and combination therapy against Elizabethkingia anophelis and the impact of reduced minocycline susceptibility. The results showed that minocycline monotherapy had a modest inhibitory effect on susceptible strains and improved survival rates in infected models, but reduced susceptibility decreased its efficacy. The addition of rifampin showed in vitro synergy, but did not provide additional survival benefits in combination with minocycline.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2022)
Article
Infectious Diseases
Mei-Chen Tan, Ying-Chi Huang, Pei-Jing Chen, Wei-Cheng Huang, Shu-Yuan Hsu, Hui-Ying Wang, Ci-Hong Liou, Jun-Ren Sun, Tsai-Ling Yang Lauderdale, Shu-Chen Kuo
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2023)
Article
Infectious Diseases
Li-Hua Li, Ya-Sung Yang, Jun-Ren Sun, Tzu-Wen Huang, Wei-Cheng Huang, Feng-Jui Chen, Yung-Chih Wang, Ting-Hao Kuo, Shu-Chen Kuo, Te-Li Chen, Yi-Tzu Lee
Summary: Acinetobacter seifertii, a new member of the Acinetobacter baumannii group, is a causative agent of severe infections in humans. This study investigated the clinical and molecular characteristics of A. seifertii in 80 adults with bloodstream infection over an 8 year period. The main source of A. seifertii BSI was the respiratory tract, with high mortality rates. Levofloxacin and carbapenems show potential as treatment options, while colistin resistance mechanisms were not associated with specific gene variations. Transmissibility of carbapenem resistance determinants was also observed in various species within the Acinetobacter group. Close monitoring of A. seifertii is warranted.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2021)
Article
Medicine, General & Internal
Yung-Chih Wang, Shu-Man Shih, Yung-Tai Chen, Chao Agnes Hsiung, Shu-Chen Kuo
Letter
Immunology
Shu-Chen Kuo, Shu-Man Shih, Li-Hsin Chien, Chao A. Hsiung
EMERGING INFECTIOUS DISEASES
(2020)